Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4184535 | 0.86 | CYP3A4 (0.52) | CYP3A4ALDH1A1CYP2C19MAPTCYP2D6 | |
| SCHEMBL13755879 | 0.86 | CYP3A4 (0.54) | CYP3A4ALDH1A1CYP2C19MAPTCYP2D6 | |
| SCHEMBL4186930 | 0.82 | LGALS8 (0.56) | CYP3A4MEN1KMT2ACYP2C9TP53 | |
| SCHEMBL4186934 | 0.82 | LGALS8 (0.56) | CYP3A4MEN1KMT2ACYP2C9TP53 | |
| SCHEMBL13755884 | 0.81 | CYP3A4 (0.63) | CYP3A4ALDH1A1CYP2C19MAPTCYP2D6 | |
| SCHEMBL12870233 | 0.81 | CYP3A4 (0.63) | CYP3A4ALDH1A1CYP2C19MAPTCYP2D6 | |
| SCHEMBL16689628 | 0.80 | CYP3A4 (0.65) | CYP3A4ALDH1A1CYP2C19MAPTCYP2D6 | |
| SCHEMBL22073058 | 0.80 | CYP3A4 (0.65) | CYP3A4ALDH1A1CYP2C19MAPTCYP2D6 | |
| SCHEMBL22710592 | 0.80 | CYP3A4 (0.65) | CYP3A4ALDH1A1CYP2C19MAPTCYP2D6 | |
| SCHEMBL4182296 | 0.80 | CYP3A4 (0.65) | CYP3A4ALDH1A1CYP2C19MAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215710-A1 | CARBOHYDRATE BASED TOLL-LIKE RECEPTOR (TLR) ANTAGONISTS | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215710-A1 | CARBOHYDRATE BASED TOLL-LIKE RECEPTOR (TLR) ANTAGONISTS | TLR4, TLR1, TLR2 | CYP3A4 1915/4885ALDH1A1 4161/4885CYP2C19 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.